Lupin receives EIR from USFDA for Vizag API Facility

14 May 2020 Evaluate
Lupin has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) after closure of the inspection for its Vizag (Vishakhapatnam), India facility. The inspection for the API facility was conducted by the USFDA between January 13, 2020 and January 17, 2020.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.

Lupin Share Price

2113.15 23.50 (1.12%)
17-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.10
Dr. Reddys Lab 1272.00
Cipla 1496.95
Zydus Lifesciences 918.35
Lupin 2113.15
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×